Myriad Genetics (MYGN) Receivables (2010 - 2026)

Myriad Genetics (MYGN) has 17 years of Receivables data on file, last reported at $123.8 million in Q1 2026.

• Receivables for Q1 2026 came in at $123.8 million, up 2.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $123.8 million (up 2.82% YoY), and the FY2025 annual result was $115.3 million, down 4.87% from the prior year.
• Receivables improved to $123.8 million in Q1 2026 per MYGN's latest filing, from $115.3 million in the prior quarter.
• Over five years, Receivables peaked at $137.0 million in Q2 2025 and troughed at $101.6 million in Q4 2022.
• A 5-year average of $116.1 million and a median of $117.8 million in 2024 frame the typical range for Receivables.
• The sharpest annual moves came in 2023 and 2025: Receivables gained 17.11% in 2023, then slipped 6.13% in 2025.
• A 5-year view of Receivables shows it stood at $101.6 million in 2022, then grew by 12.5% to $114.3 million in 2023, then gained by 6.04% to $121.2 million in 2024, then decreased by 4.87% to $115.3 million in 2025, then climbed by 7.37% to $123.8 million in 2026.
• Business Quant data shows MYGN's Receivables at $123.8 million in Q1 2026, $115.3 million in Q4 2025, and $118.0 million in Q3 2025.